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Mini-ISES identifies promising carbafructopyranosebased salens for asymmetric catalysis:
Tuning ligand shape via the anomeric effect
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Kannan R. Karukurichi, Xiang Fei, Robert A. Swyka, Sylvain Broussy, Weijun Shen,
Sangeeta Dey, Sandip K. Roy, David B. Berkowitz*
This study introduces new methods of screening for and tuning chiral space and in so doing identifies a promising
set of chiral ligands for asymmetric synthesis. The carbafructopyranosyl-1,2-diamine(s) and salens constructed
therefrom are particularly compelling. It is shown that by removing the native anomeric effect in this ligand family,
one can tune chiral ligand shape and improve chiral bias. This concept is demonstrated by a combination of (i) x-ray
crystallographic structure determination, (ii) assessment of catalytic performance, and (iii) consideration of the anomeric effect and its underlying dipolar basis. The title ligands were identified by a new mini version of the in situ
enzymatic screening (ISES) procedure through which catalyst-ligand combinations are screened in parallel, and
information on relative rate and enantioselectivity is obtained in real time, without the need to quench reactions
or draw aliquots. Mini-ISES brings the technique into the nanomole regime (200 to 350 nmol catalyst/20 ml organic
volume) commensurate with emerging trends in reaction development/process chemistry. The best-performing
b-D-carbafructopyranosyl-1,2-diamine–derived salen ligand discovered here outperforms the best known organometallic and enzymatic catalysts for the hydrolytic kinetic resolution of 3-phenylpropylene oxide, one of several
substrates examined for which the ligand is “matched.” This ligand scaffold defines a new swath of chiral space,
and anomeric effect tunability defines a new concept in shaping that chiral space. Both this ligand set and the
anomeric shape-tuning concept are expected to find broad application, given the value of chiral 1,2-diamines and
salens constructed from these in asymmetric catalysis.

INTRODUCTION
As part of a program directed at streamlining the process for discovering useful new reactivity and for identifying useful catalytic ligandmetal combinations, we have been laying the groundwork for an in situ
enzymatic screening (ISES) approach to reaction screening. Although
it is clear that reaction development requires a balance between screening and hypothesis-driven or computational (1, 2) approaches, in looking for fundamentally new reactivity, a broad initial screen can be of
great use. This point is underscored through the recent successes of
the groups of MacMillan (3) and Hartwig (4) in exploratory screens
to “accelerate serendipity” yielding amine a-arylation, and Cu-mediated
alkyne hydroamination transformations, respectively, and Chirik’s identification of an earth-abundant Co system for asymmetric alkene hydrogenation (5). Beyond this, recent advances in multicomponent reactions
highlight the payoff attainable in systems with additional reactants (6–8)
or catalytic entities (9–13). In such endeavors, once reactivity space is better defined, Sigman has shown that one may be able to tune the transformation, for example, by using empirical “sterimol” parameters (14).
The desire to interrogate catalyst structure/reactivity space broadly
has spurred a parallel innovation in catalyst screening technology (15, 16).
On-bead catalyst libraries have been exploited to enhance throughput
with readouts including infrared thermography (17, 18) and gel-zone
fluorescence (19, 20). More recently, microfluidic approaches have been
invoked to address throughput (21–23). Optical sensing methods continue to be invoked and include fluorescence resonance energy transfer
(24), indicator-displacement assays (16, 25), substrate chromophore induction (26), and optical rotatory dispersion (27). Mass spectrometric
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*Corresponding author. E-mail: dberkowitz1@unl.edu

Karukurichi et al. Sci. Adv. 2015;1:e1500066

10 July 2015

methods have proven invaluable to enhance throughput (4, 28) and
provide information on reactivity (29) and stereoselectivity (30, 31). Perhaps inspired by the “combinatorial” path by which polypeptide catalysts evolve in nature, a number of successful “evolved” small-molecule
catalysts feature peptidomimetic elements (32–40), perhaps none more
strikingly than the catalyst suite developed by Miller and co-workers
(41–44). Conversely, given both the inherent ability of enzymes to both
differentiate stereoisomers and the opportunity to potentially leverage
spectroscopic signals associated with a number of enzymatic transformations, we (45–51) and others (52–60) have developed protein-based
sensing methods to facilitate the combinatorial catalysis enterprise.
Described herein is a miniaturized version of ISES (47) that is inspired by the recent disclosure from the Merck Process Group of a
synthesis optimization platform that reduces volumes and quantities
dramatically, down to the nanomole, for high-throughput chemistry development (61), by taking advantage of robotic instrumentation (62, 63).
This report demonstrates proof of principle of mini-ISES, by using an
ultraviolet (UV)/visible (vis) spectrophotometer outfitted with a quartz
micromulticell for the biphasic catalyst screening method, thereby reducing the amount of catalyst needed per screen to the level of 200 to
350 nmol. This is done without specialized equipment, setting the
stage for much higher-throughput, robotic versions of the technique,
by demonstrating that catalysts can be effectively characterized from
the reporting enzyme traces obtained on this nanomole scale, within
minutes, and on the fly. The mini-ISES technique is applied here for
the exploration of novel chiral space, with the goal of identifying fundamentally new scaffolds for asymmetric catalysis.
As one thinks about organizing chiral space for the design of asymmetric catalysts, the notion of symmetry often emerges. It has been argued,
for example, that by building C2-symmetry into a ligand or catalyst,
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one limits the number of chiral approaches available to substrate. In
addition, although this can certainly be advantageous, as is illustrated
in Fig. 1, “privileged chiral scaffolds” (64) for asymmetric catalysis are
known that present chiral space in both C2-symmetric (A) and non–
C2-symmetric senses (B). It is important to explore both topological
domains in seeking to identify new chiral motifs of value (65). Among
the chiral elements that have been invoked to carve out useful chiral
space is axial chirality, from established ligands such as the BINAPs
(Noyori) (66) to exploratory ligands being developed today around
aniline systems with hindered rotation about C–N bonds (Curran)
(67). Planar chirality is now an established chiral element, as highlighted by the success of the Phanephos (Pye) (68) and Josiphos ligands
(Togni) (69), as well as related ferrocene-based scaffolds (70), including
planar chiral “DMAP equivalents” (Fu) (71). Helical chirality is a chiral
element still in its infancy for the chiral ligand design, with important
recent contributions from Takenaka (72, 73).
A

B

C2 symmetric
Et

That said, catalysts projecting central chirality in a non–C2symmetric sense are of great importance in modern asymmetric synthesis,
including those derived from chiral pool elements. These include prolinebased oxazaborolidines (Itsuno, Corey) (74, 75) and proline-containing
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Fig. 1. “Privileged” chiral scaffolds. (A) C2-symmetric scaffolds for asymmetric catalysis. Cinchona alkaloids (teal); trans-1,2-diaminocyclohexane systems
(blue); TADDOLates (orange); Phanephos-planar chirality, helically chiral bipyridyl-type ligand (wine); BINAP systems (green). (B) Non–C2-symmetric scaffolds.
Cinchona alkaloids (teal); trans-1,2-diaminocyclohexane-based Strecker catalyst (blue); proline-based systems-oxazaborolidine (red); Phanephos-planar chirality, helically chiral bipyridyl ligand (wine); planar chiral ferrocenyl phosphine systems (purple); CH-activated Ir-phosphoramidite catalyst (green). Arrows
indicate the conversion of C2-symmetric systems into non–C2-symmetric systems.
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structures for neuroactive ligands (96). The concept persists in medicinal
chemistry circles and has been discussed more recently by Stockwell (97).
In such discussions, ligands are presumed to have a particular propensity
to bind to a range of protein targets and influence function. “Privileged
chiral ligands,” on the other hand, it might be said, have a particular propensity to impart useful chiral bias to a catalytic center, usually upon ligation to a metal. This concept appears to have evolved from the
medicinal chemistry concept and has been widely discussed in synthetic
chemistry circles since the provocative piece in Science by Yoon and Jacobsen in 2003 (64).
Perhaps most interesting in this discussion of “privileged” chiral
space and symmetry is the observation that depending on the system,
advantage can be gained from both inducing C2-symmetry where it is absent and breaking C2-symmetry where it is present (see arrows depicting
these “symmetry crossovers” in Fig. 1). Thus, Sharpless and co-workers
generally improved upon the first-generation dihydroxylation ligands
by constructing bidentate cinchona ligands into which a new C2-axis
is thereby built (98). On the other hand, while retaining the trans-1,2diaminocyclohexane chiral scaffold from the “privileged” Jacobsen-type
salens (64) and Trost-type bis-phosphines (99) , Jacobsen and Sigman
later found it advantageous to place this same chiral scaffold into a
non–C2-symmetric system, presumably to generate a more enzymelike system, with dual catalytic roles, in building an asymmetric Strecker
catalyst (40). Perhaps most interesting in this category is the fortuitous
finding by Hartwig and associates that “privileged” C2-symmetric
phosphoramidite ligands pioneered by Feringa (100–102), at least in
the context of Ir-catalyzed allylic amination, lead to a very effective
iridicyclic catalyst through a symmetry-breaking C–H activation event
(103–105).
Our approach herein was to examine non–C2-symmetric central
chirality, and to investigate topologies not previously explored (106),
with a particular focus on chiral 1,2-diamines and their derivative
salens as chiral motifs with wide-ranging potential in asymmetric catalysis. Systems built around amino acid, terpenoid, and carbohydrate
scaffolds were initially explored. A new set of interesting salen ligands
built around the fructopyranosyl-4,5-acetonide emerged from these
studies. We use mini-ISES to fingerprint the asymmetric profile of a
focused array of ligands of this new class here. Key variables that have
emerged include the ability to tune the shape of these ligands through the
presence or absence of an anomeric effect and the ability to pair such
non–C2-symmetric 1,2-diamines with nonsterically demanding salicylaldehyde equivalents, to produce the most selective salen ligands
yet observed, particularly in cases of “matched” substrates.

RESULTS
In the cassette ISES approach, multiple candidate catalytic combinations
are screened in an information-rich parallel format. The experimentalist
gleans data on relative rate, sense and magnitude of enantioselectivity,
and substrate generality for the catalyst candidates being evaluated. The
process is truly in situ, obviating the need to take aliquots or quench the
reaction to obtain readouts on reaction progress. The hydrolytic kinetic
resolution (HKR) serves as a very useful platform for both the investigation of new catalyst screening modalities and the development of new
salen ligands, with the picture of a stereochemistry-determining transition state involving bimolecular metal-salen participation (vide infra)
emerging (107–110).
Karukurichi et al. Sci. Adv. 2015;1:e1500066
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Mini-ISES
The experimental configuration developed for mini-ISES is illustrated
in Fig. 2 for the screening of Co(III)-salen catalysts for the HKR of
epoxides, using both (±)-propylene oxide and (±)-hexene oxide as test
substrates. The product 1,2-diols diffuse from the lower organic layer
(20 ml) into an upper aqueous buffer layer (90 ml) containing reporting
enzymes that oxidize the product, resulting in the conversion of NAD+
(nicotinamide adenine dinucleotide) to NADH (reduced form of NAD+)
with a concomitant increase in the Abs340 observable by UV/vis spectroscopy. The experimental setup used herein uses 4 of 16 available
110-ml wells in a single quartz micromulticell per catalyst candidate
and substrate pair, significantly streamlining the process. Additionally,
as is described in detail below, three new KRED (ketoreductase; Codexis
naming system) reporting enzymes have been identified, also serving
to facilitate implementation of this information-rich, in situ screening
methodology. Specifically, KRED 23 was found to be a complement to
TBADH (Thermoanaerobium brockii alcohol dehydrogenase) for following the HKR of propylene oxide. The former is selective for (S)-1,2propanediol and the latter for the (R)-antipode (see the Supplementary
Materials for detailed kinetic analysis and data). For the HKR of hexene
oxide, KRED 119 was identified as an (R)-selective reporting enzyme
and KRED 107 as a highly (S)-selective enzyme.
After considerable experimentation with these reporting enzymes
and the quartz micromulticell platform, it was found that the aqueous
reporting layer could be reduced from 500 ml (cuvette-ISES) to 90 ml.
The organic layer volume could be reduced from 300 to 20 ml in the
micromulticell well, allowing for a significant reduction in the amount
of catalyst/substrate needed for screening. Even under these mini-ISES
conditions, reliable UV/vis spectroscopic traces were obtained from the
reporting enzyme window. In terms of loading for mini-ISES, it was
found that under optimal conditions, one can obtain useful ISES
traces using only 200 to 350 nmol of active Co(III)-salen catalyst
(0.25 mol %) within minutes (Fig. 2B). The salen ligand stereopreference
profiles obtained are presented below, following a discussion of the design
of this focused salen array and the synthesis of this new ligand class.
Design of the salen array
The original salen array that we assembled for double cuvette-ISES
(48) was composed of 1,2-diamines derived from the chiral pool. Terpenoid, amino acid, and carbohydrate scaffolds were all fashioned
into 1,2-diamines that were combined with variously substituted salicylaldehyde or a-hydroxy aryl aldehyde partners to generate the
salen/pseudosalen array. Two particularly intriguing new salen motifs
emerged from those early studies. On the one hand, a salen derived
from the b-pinene–derived 1,2-diamine and a-hydroxynaphthaldehyde
showed high E values for the HKR of matched terminal epoxides. This
chiral diamine was new to asymmetric synthesis and was inspired by
the success Midland (111) and Brown (112) had enjoyed in building
chiral organoboron reagents from the a-pinenoid scaffold, most notably Alpine-borane and DIP-chloride. Indeed, this terpenoid b-pinene–
derived pseudosalen ligand served as the source of all chirality in the
rapid asymmetry assembly of the antipodal oxabicyclo[4.3.1]dodecyl
cores of the sesquiterpene lactone natural products zaluzanin A and
linearifolin in these laboratories (45).
D-Carbafructopyranose–based 1,2-diamines
The more provocative ISES lead was generated by exploring the
fructopyranose scaffold as a new chiral scaffold around which to build
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Fig. 2. Depiction of the mini-ISES format for information-rich catalyst screening (ee, relative rate, and substrate scope). (A) Quartz micromulticell
in the background; reporting wells for catalyst derived from salen 16a in the foreground featuring both (S)- and (R)-selective dehydrogenase reporting
enzymes for both propylene oxide (KRED 23 and TBADH, respectively) and hexane oxide (KRED 107 and KRED 119, respectively). The protein structure
shown is the actual structure of TBADH (PDB 1YKF). (B) Actual ISES data for the HKR of the respective epoxides mediated by the Co(III)-salen catalyst
derived from 16a in the lower organic layer (20 ml); spectral data reflect the conversion of NAD(P)+ to NAD(P)H upon diol oxidation by the respective
reporting enzyme, with the concomitant increase in Abs340 nm versus t (min).

1,2-diamines. Prior to our work, D-fructose–based chirality had been
used in both the furanose form (diphosphite ligands for Ni-mediated
alkene hydrocyanation) (113) and the pyranose form in the seminal
work of Shi (114, 115), in which the 3-position of the sugar supports
a chiral dioxirane moiety for alkene epoxidation. Against that backdrop, we chose to explore the D-fructopyranose-4,5-acetonide scaffold
as a bicyclic chiral 1,2-diamine backbone. This appears to be the first
example of the use of fructose-based chirality in 1,2-diamine ligand
design. Figure 3 illustrates how the a- (5) and b-D-fructopyranosyl1,2-diamines (6) can be readily assembled in six steps from D-fructose
itself. Because of promise seen in the D-fructopyranose–based 1,2diamines as new chiral motifs for asymmetric catalysis and the desire
to prevent anomerization, it was decided to explore the corresponding
carbocyclic system.
Karukurichi et al. Sci. Adv. 2015;1:e1500066
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Our initial entry into the projected D-carbafructosyl-1,2-diamine
scaffold emanates from (−)-quinic acid, as outlined in Fig. 4. The selective capture of the quinate carboxylic acid functionality as the 1,3diaxially disposed lactone is based on the elegant work of Shing (116).
This permits for the simultaneous blocking of the remaining vicinal
diol via a cyclohexanone-derived ketal. Lactone cleavage then releases
a single secondary alcohol allowing for site-selective oxidation. Pyridinium
chlorochromate (PCC)–mediated oxidation then proceeds smoothly with concomitant elimination of the tertiary alcohol into the a,bunsaturated ketone 8. Sodium borohydride–mediated carbonyl reduction
from the convex face followed by tranketalization leads to a,bunsaturated ester 9. Barton deoxygenation is followed by bis-Grignard
addition into the methyl ester, giving triol 10. The triol was selectively
O-methylated at the lone secondary alcohol in the triol followed by
4 of 20
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Fig. 3. D-Fructopyranosyl-1,2-diamine synthesis.

oxidative cleavage of the vic-tert-diol with Pb(OAc)4 to yield stereodefined ketone 12. Subsequent Wittig methylenation produced the
desired carbofructose-leading olefin 13 in 80% yield. Next, the key
step, diazidation of the exocyclic alkene, was realized, adopting a procedure
developed by Snider and co-workers (117). Namely, Mn(OAc)3-mediated
alkene diazidation delivered the D-carbafructopyranosyl-1,2-diazide as
a mixture of the anticipated a- (14) and b-pseudo-anomers (15). After
chromatographic separation, these diastereomeric diazides were hydrogenated to give the respective diamines, 16 and 17, as desired, in
quantitative yield.
Assembly and screening of focused
carbafructopyranose-based Co(III)-salen array
With both the oxa- and carbacyclic fructopyranosyl-1,2-diamines in
hand, we next constructed a focused library of Co(III)-salen catalysts
as depicted in Table 1. The a- and b-diastereomers of both the oxacyclic
(5, 6) and carbocyclic D-fructopyranosyl-1,2-diamines (16, 17) were
paired with salicylaldehydes bearing varied 3′,5′-substitution patterns
[di- (a) or mono-t-butyl (b), diiodo (c)], as well as with the a-hydroxyb-naphthaldehyde (d). Each salen was converted to the Co(II)-salen
(precipitates out) by incubation with Co(OAc)2 in MeOH. Immediately
before performing HKR runs, the Co(II)-salen was converted to the
Co(III)-salen(DNB) complex, by air oxidation in the presence of
3,5-dinitrobenzoic acid.
The newly developed mini-ISES was used for a rapid screening. As
discussed, on the basis of diol oxidation efficiency and stereoselectivity,
KRED 107 and KRED 119 were selected as reporting enzymes for the
HKR of (±)-hexene oxide, whereas KRED 23 and TBADH were used
to screen the HKR of (±)-propylene oxide. Then, by using a standard
UV/vis apparatus, outfitted with the quartz micromulticell, the focused salen array could be expeditiously screened across both test substrates (see the Supplementary Materials for detailed characterization).
Karukurichi et al. Sci. Adv. 2015;1:e1500066
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ISES-estimated ee values were compared with the measured ee values under typical flask conditions. Three-dimensional (3D) bar graph
representations of these results are depicted in Fig. 5. The ISES screen
involves biphasic organic (CHCl3, epoxide)/aqueous conditions, wherein
one sample diol product diffuses into the aqueous layer at early times
and with minimal catalyst loading (0.25 mol %). On the other hand,
the “flask conditions” here involve incubation of Co(III)-salen catalyst
in neat epoxide, with 0.55 eq. water, at longer times (3 hours) and somewhat higher catalyst loading (0.5 to 1 mol %). The goal is to explore how
well a rapid early screen serves to predict kinetic resolution efficiency.
As can be seen in the 3D bar graph patterns for ISES estimations of
product ee at early times (Fig. 5, left side, blue/green bars) versus the
high-performance liquid chromatography (HPLC) determinations of
product diol ee under flask conditions (right side, pink, aqua bars), ISES
serves as a useful, predictive screening tool here. In particular, one notes
the clear (S)-selectivity of both Co(III)-5c-DNB and Co(III)-17c-DNB
from the paired positively oriented bars, representing the two test substrates across both bar graphs. These catalysts, particularly those derived from the novel b-D-carbafructopyranosyl-1,2-diamine, 17c, emerged
from this focused screen as worthy of much greater study here. From
a catalyst screening point of view, these initial studies demonstrate
proof of principle for the ability to obtain reliable ISES data in this
new micromulticell format, that is, mini-ISES. Recall that these data
were obtained with the 20-ml organic layer/90-ml aqueous reporting
layer volumes described and required nanomolar levels of catalyst
per micromulticell well.
Structure/enantioselectivity relationships
In examining the patterns seen in this focused salen library screen, two
interesting observations emerge, both unexpected and both useful in
thinking about ligand structure/enantioselectivity relationships. First,
in both the carbacyclic and oxacyclic series, an “enantioswitch” is
5 of 20
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observed based on the substituent on the salicylaldehyde and not the
chiral element, that is, the D-fructopyranose–based 1,2-diamine. Specifically, when evaluated for the HKR of propylene oxide and hexene
oxide, the Co(III)-salen catalyst derived from the pairing of the b-Dcarbafructopyranose-1,2-diamine (17) with 3,5-di-tert-butylsalicylaldehyde
(a) gives rise to the (R)-diol products, whereas the catalyst derived from
pairing of this same chiral diamine (17) with 3,5-diiodosalicylaldehyde
(c) gives the corresponding (S)-diol products. This is the same pattern
that is seen in the oxacylic (native fructose-derived) series with the
true b-D-fructopyranosyl-1,2-diamine (that is, 6a versus 6c). However,
given that 6 and the corresponding a-anomer 5 can interconvert via
an anomerization mechanism, one could always hypothesize that in
the oxacyclic series, an undetected anomerization might somehow underKarukurichi et al. Sci. Adv. 2015;1:e1500066
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lie this apparent “enantioswitch” in catalyst preference. The result with
the carbacyclic system (that is, 17a versus 17c) now seems to firmly
rule out this “undetected anomerization” mechanism for change of
enantiopreference in the oxa-fructopyranose series. The overall result
here is important. Namely, within the context of these new carba- and
oxacyclic b-D-fructopyranosyl-1,2-diamine chiral scaffolds, one can alter the sense of enantiopreference and improve the magnitude of
enantioselection by moving from the more sterically encumbering
3′,5′-di-tert-butyl substitution pattern on the salen to the less sterically
encumbering 3′,5′-diiodo substitution pattern.
However, probably the most interesting and informative observation made here is the notable enantioselectivity improvement from the
oxafructopyranose-based ligand 6c to the carbafructopyranose-based
6 of 20

RESEARCH ARTICLE
Table 1. HKR screening of focused oxa/carbafructopyranose-derived salen array. Each box provides the HKR data of propylene oxide (black) and
hexene oxide (blue) under the catalysis of the corresponding Co(III)-salen 3,5-dinitrobenzoate. The ISES-estimated % ee values of the produced diols are
presented in brackets, followed by the observed % ee values (chiral HPLC) and calculated E values.

CHO

CHO
t

t

Bu

O
O
O

#
25(+)

[70(+)]
42(+)

[67(+)]
40(+)

5

6.2(+)

4.0(+)

2.6(+)

2.4(+)

[33(−)]
64(−)

#
52(−)

[28(−)]
40(−)

[31(−)]
36(−)

[85(+)]
83(+)

[77(+)]
85(+)
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4.2(−)

2.5(−)

2.4(−)

13(+)

28(+)

[53(−)]
37(−)

[23(−)]
29(−)

[76(−)]
75(−)

[40(−)]
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[42(−)]
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44(+)
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6
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O
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¶

§

1.7(+)

NH2
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OMe
O

d

[64(+)]
45(+)

Me

O

c

Me

O

O

I

b

[77(+)]
69(+)

NH2

O
O

Me

Bu

NH2

Me

O

t

a

OH

OH

I

Me

O

Me

OH

OH

Bu

CHO

CHO

NH2
NH2

17

¶Difficulty was encountered in synthesizing appreciable quantities of this salen.

#These catalysts gave negligible ISES rates.

ligand 17c. Replacing the ring oxygen with a methylene confers a significantly higher (S)-selectivity upon the resulting Co(III)-salen complex,
with an about three- to fourfold increase in E value—from 13 to 44
and from 28 to 104 for the HKR of the propylene and hexene oxides,
respectively. This experimental observation prompted us to examine
the underlying structural basis of such a dramatic change in chiral bias
by single atom replacement. Of course, it had not escaped our attention that this particular single-atom replacement could have important
structural consequences, as one would be effectively removing a ground
state anomeric effect, such as it is, in such a diamino-sugar system.
For these reasons, complete crystallographic characterization of these
Co-salens was undertaken and provides important insight in this regard, as is discussed in detail below.
Benchmarking performance for the
carbofructopyranosyl-1,2-diamine–derived salen-17c
To assess the potential of the most promising ISES hit for asymmetric
catalysis, the top mini-ISES hit, catalyst Co(III)-(17c)-DNB, was next
taken well beyond the screening set and examined for its HKR perKarukurichi et al. Sci. Adv. 2015;1:e1500066
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§

§

§

[13(−)]
34(−)
2.2(−)

§These catalysts gave a conversion < 2% after 72 hours.

formance across a range of differentially structured and substituted
epoxide substrates. The results are collected in Table 2. Given the difficulty in obtaining accurate values for the selectivity factor for any
kinetic resolution, we find it useful to measure yield and ee of both
the remaining epoxide and the product diol, in each case. This provides two independent measures of enantioselectivity for each entry and,
we feel, lends more confidence in assigning these values as a measure of
catalyst performance with a particular substrate. The results are rather
striking. The Co(III)-17c-DNB catalyst exhibits excellent HKR results
with three substrates, displaying E values in the range of 40 to 50, whereas
nearly perfect resolutions are obtained for another three substrates,
namely, hexane oxide, O-phenylglycidol, and 3-phenylpropylene oxide.
For benchmarking purposes, the latter two epoxides are of particular interest, because they have been the targets of both asymmetric
metal-salen–based and biocatalytic efforts directed at developing
new and efficient HKR catalysts. (1a) For O-phenylglycidol, trans1,2-diaminocyclohexane–based Co(III)-salens have been used by
both the Schulz (118) and Jacobsen groups, with reported E values
ranging from 60 (54% conversion) to 120 (18% conversion), respectively.
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Fig. 5. Three-dimensional bar graph for data from miniaturized ISES-for the Co-salen array. (A) ISES data displayed in 3D format. (B) Comparison data from flask reactions (see the Supplementary Materials for details). (C) Sixteen-well quartz micromulticell used for mini-ISES. Note:
Positive deflection = S-selective; blue, pink = HKR of hexane oxide; green, aqua = HKR of propylene oxide.

(1b) On the enzymatic side, Reetz and co-workers have carried out
two separate directed evolution studies, both emanating from native
Aspergillus niger epoxide hydrolase (ANEH) and both directed at developing enzymatic catalysts optimized for the HKR of O-phenylglycidol.
In the first case, 20,000 clones were generated in a five-step process resulting in an evolved ANEH with nine point mutations and an E value
of 115 (119). A more recent study, in which ePCR was first used, expression levels led to a new ANEH variant with seven point mutations,
plus a 13-mer peptide insertion (apparently an unintended consequence
of the QuikChange protocol for site-directed mutagenesis) (120). This
new directed evolution mutant shows an E value of 160 for the HKR of
O-phenylglycidol. Thus, Co(III)-17c shows a chiral bias (E = 95 ± 2 at
51% conversion) comparable to the best-known chiral Co-salen catalyst
(E = 90 ± 30 at 18 to 54% conversion) but somewhat lower than the
best-evolved enzymes for this reaction (E = 115; 160). For the HKR of
3-phenylpropylene oxide, (2a) the trans-1,2-diaminocyclohexane–based
Co(III)-salen due to Jacobsen is the most selective metal-organic catalyst
previously reported, with E = 96 (20% conversion) (110). (2b) In the
enzymatic realm, in this case, the Widersten group recently described
the directed evolution of a plant enzyme, Solanum tuberosum epoxide
hydrolase (StEH), targeted at the HKR of this substrate. Through four
cycles of directed evolution, the best variant featured five point mutations
and displayed E =14 (121). Then, the Co(III)-17c catalyst introduced
here shows a chiral bias (E = 106 ± 13 at 51% conversion) that is
at least equivalent to the best-known chiral salen catalyst (E = 96 at
Karukurichi et al. Sci. Adv. 2015;1:e1500066
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20% conversion) and superior to the best enzymatic catalyst (E =14)
yet described.
X-ray crystallographic analysis: Tuning ligand shape via the
anomeric effect
To gain further insight into the chiral space mapped out by these new
chiral ligands and into the structural basis of the enantiopreferences
displayed by the most promising catalyst, we next set out to obtain
diffractible crystals. We report here the x-ray crystal structures of three
Co(II)-salen complexes, namely, those derived from salens 6a, 6c, and
17c. The 3D structures of each of these three new D-fructopyranose–
derived salen scaffolds are displayed in Fig. 6. One sees very clearly
that whereas both oxacycles assume a distorted 3,6B boat-like structure
for the pyranose ring, the carbacycle displays a 5C2 chair-like geometry.
The information gleaned here suggests that the shape of these ligands
can be “tuned” by the anomeric effect (122). Thus, in the absence of an
anomeric effect, in the carbacycle, the sterics of the Co(salen) system are
apparently such as to favor a 5C2 conformation for the cyclohexyl ring
as is revealed by the structure of Co(II)-17c (Fig. 6C). Introduction of
the ring oxygen into this system would produce the 5C2 conformation
depicted in Fig. 6A for the Co(II)-6c complex. As can be seen, this
would introduce an unfavorable reinforcing dipole-dipole interaction
between the anomeric C–N bond and the ring dipole (123). Distortion
of the amino sugar core from a 5C2 conformation to a 3,6B conformer
(Fig. 6B) serves to relieve this dipolar strain, thereby changing the shape
8 of 20
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Table 2. Overview of HKR performance of the Co(III)-dinitrobenzoate catalyst derived from salen 17c. rt, room temperature.

Entry

H
1

H

H

H

O

4
O

H

H

H

8

45

50, −74, 44

46, 88, 34

0.5

DCM, rt, 20 hours

51

47, −96, 97

46, 92, 93

0.5

Neat, 0oC, 30 hours

52

45, −99, 104

48, 91, 116

0.5

Neat, 0oC, 23 hours

51

48, −97, 119

49, 92, 93

1.0

THF, rt, 35 hours

44

55, −72, 49

40, 92, 52

0.5

Neat, rt, 30 hours

54

40, −99, 61

48, 82, 40

0.5

DCM, rt, 20 hours

32

68, −39, 16

26, 86, 20

1.0

THF, rt, 50 hours

28

63, −33, 17

28, 90, 27

O

O
Ph Ph
tBu Si O

Neat, 0oC, 15 hours

O

H

7

Isolated diol

O

N
H

H
6

Isolated epoxidec

0.14

O

H3C

tBuO

Conversionb

O

O

3

Conditionsa

O

Me

2

5

Catalyst loading
(mol%)

Epoxide educt (±)

H

O

a

Catalyst (0.2 to 1 mol %) was added to a solution of epoxide in THF or DCM or neat condition. The mixture was cooled to 0°C or kept at room temperature and 0.5 equivalent water was added to
b
c
Conversion of the reaction was determined by 1H NMR.
The purified yield (black), % ee (red), and
initiate the reaction. The reaction was stirred at 0°C or room temperature until completion.
calculated E value (blue) are listed consecutively. Note: All diol products are presumed to be (S)-configured but, for entry 2, due to a change in Cahn-Ingold-Prelog prioritization. A negative sign as prefix
for the % ee designates that the epoxide is (S)-configured.

of the ligand, the chiral space that it maps out, and the chiral bias that
it manifests in the HKR reaction.
There is good precedent for the anomeric effect playing an important role in the pyranose forms of the parent sugars for all four of the
diastereomeric ketohexoses. Thus, both b-D-fructopyranose (124) and
b-D-psicopyranose (125) are known to assume the 2C5 chair, whereas
both a-D-tagatose (126) and a-L-sorbose (127) exist predominantly
in the 5C2 chair as pyranoses. In all such cases, the anomeric C–O
bond is oriented so as to partially oppose the ring dipole. The amino
sugar salens being investigated here differ from the parent sugar pyranoses, both in having an unusual anomeric C–N bond and in having
both the C1- and the C2-nitrogens engaged in a rigid Co-salen ring
system. We believe that this has the effect of distorting the normally
favored chair conformer into a boat-like conformer that nonetheless
displays a favorable anomeric effect (partially opposing dipoles) as is
seen the structures for both Co(II)-6c and Co(II)-6a (Fig. 7, B and D,
respectively). The removal of the ring oxygen in these systems not only locks out anomerization but also reshapes the ligand, by removing
Karukurichi et al. Sci. Adv. 2015;1:e1500066
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this boat-enforcing anomeric effect, generating an even more enantiodiscriminating chiral scaffold.
Considering bimolecularity in the HKR transition state
In seeking to model the favorable chiral bias (Table 2) exhibited by the
Co(III)-17c-salen catalyst, we began from the crystal structure
coordinates of the corresponding Co(II)-17c complex. Modeling was
guided by three key observations from the Co(III)-salen HKR literature. (i) First, careful kinetic studies by Blackmond and Jacobsen indicate that two molecules of Co(III)-salen are involved in the HKR
mechanism (109), one to deliver the hydroxide nucleophile to the epoxide
and the other [likely bearing a DNB counterion (108); a second molecule of Co(III)-salen–OH is used here for the model] as a Lewis acid.
Density functional theory (DFT) studies agree with these experimental
observations, finding that a cooperative, bimolecular SN2-like pathway
for Co-salen–mediated epoxide hydrolysis is favored over unimolecular alternatives (128). (ii) The Chin crystal of an aziridine Co(III)salen complex was used to guide both the coordination distance and
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Fig. 6. X-ray crystal structures of Co-salen complexes reveal a correlation between anomeric effect and ligand shape in this ligand family.
(A) Schematic drawing of the proposed distortion of a 5C2-like conformation into a 3,6B-like conformation to minimize dipole-dipole repulsion in Co(II)-6c,
as a manifestation of the anomeric effect. (B to D) X-ray crystal structures of (B) Co(II)-6c, (C) Co(II)-17c, and (D) Co(II)-6a.

coordination angle of the Co-salen–bound epoxide (129). (iii) A recent
DFT computational study by Jacobsen and co-workers posits that key
stereoelectronic control elements are at play in such Co-salen–mediated
epoxide openings. Their studies project that the O–Co–O–C dihedral
angle (q) is critical, with the energy well for productive coordination
complexes displaying a shallow minimum, suggesting that dihedral
angles approximately in the 20 to 60° range are optimal (107).
As noted above, x-ray crystallography reveals a chair-like carbasugar
ring in the Co(II)-17c structure. The Co(III)-17c-OH complex was built
from these crystallographic coordinates, followed by docking of a typical terminal epoxide substrate, taking care to minimize unfavorable
van der Waals interactions in so doing. The model obtained is presented
in Fig. 8. (S)-hexene oxide is coordinated to the Co(III) center at 1.99 Å,
close to the Co–N distance in the Chin crystal structure (1.95 Å). In
addition, the oxirane ring approaches the Co center at an angle (122 ±
18°) modeled after that of the bound aziridine (123 ± 3°) in this structure. The dihedral angle is 24°, close to the O–Co–N–C angle observed
in the Chin structure (33°) within the domain of the shallow minimum identified by the Jacobsen group. Adhering to these constraints,
the (S)-hexene oxide substrate is well positioned underneath the p face
of HO-Co-salen moiety, a face that is particularly accommodating
with diiodo substitution. Finally, Jacobsen also puts forth the notion
that enantioselection in such biomolecular salen-epoxide complexes
may be governed by the overall stepped conformation of the Co-salen
Karukurichi et al. Sci. Adv. 2015;1:e1500066
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complex (107). To investigate this in the context of the new Co-salen
complexes described here, the step heights for each of the three Cosalen crystal structures were estimated (see the Supplementary Materials for details) with the observation that the Co(II)-17c complex also
displays the largest step height of the set at 0.76 Å. That the fructopyranosebased Co-salen complexes being investigated here by both crystallography
and chiral bias display a similar structure/enantioselectivity relationship
to that seen by Jacobsen and co-workers lends support to the notion
that these systems proceed through similar mechanisms (for example,
as modeled in the bimolecular transition state envisioned in Fig. 7).
Streamlined synthesis of b-D-carbafructopyranosyl-1,2-diamine
Given the promise shown by this previously undescribed b-Dcarbafructapyanosyl-1,2-diamine chiral scaffold, we have now also
developed a streamlined, second-generation entry into this system
beginning from a cheap, readily available starting material, a-methylD-mannopyranoside (Fig. 8). Thus, an Appel reaction efficiently transforms the 6-hydroxyl into the 6-iodide. The requisite acetonide may
then be selectively installed across the cis-configured vicinal 2,3-diol
through exposure to dimethoxypropane/acetone with catalytic p-TsOH.
C-4-O-methylation and dehydrohalogenation can then be achieved in
a single step, in nearly quantitative yield, giving enol ether 19. For the
key type II Ferrier rearrangement, several divalent, late-transition
metal catalysts [HgCl2, Pd(OAc)2, and PdCl2] were examined, with
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variation of solvent and temperature. The optimal conditions identified use 10 mol % Pd(OAc)2 in a mixture of acetone, dioxane, and water
(40:40:20) at 0°C, providing rearranged product 20 in 85% yield. The
temperature proved to be critical, with warming the reaction to room
temperature resulting in unwanted side products. To remove the resultant hydroxyl group in 20, Barton deoxygenation was initially envisioned. However, the projected phenyl thionocarbonate ester proved
to be unstable and tended to be eliminated upon exposure to silica gel. This
observation led us to modify the route, adding an O-mesylation step to
facilitate in situ b elimination to the a,b-unsaturated ketone intermediate
in 80% yield. Hydrogenation then gives 12, the key intermediate in the
synthesis of 17c, in quantitative yield. The newly developed synthesis saves
six steps, raises the overall yield more than fivefold compared to the firstgeneration route from (−)-quinic acid, and also begins from a more economical starting material, namely, D-mannopyranose.

DISCUSSION
Inspired by recent developments in leading process chemistry groups
to reduce the scale for reaction development and catalyst optimization
down to the nanomolar regime (61), we report here a mini-ISES screen
that exploits a quartz micromulticell for parallel screening of catalysts
in 20-ml organic volumes at 200 to 350 nmol of catalyst loading. The
technique is used to probe for diamine ligands and their derivative
salens that map out new and potential useful chiral space for asymmetric catalysis. Out of these efforts emerged a new chiral motif built
around the non–C2-symmetric b-D-fructopyranosyl-1,2-diamine and
its cognate carbacycle, particularly when combined when the sterically
unencumbered 3′,5′-diiodosalicylaldehyde, to build salen ligands with
promise for asymmetric catalysis. In pairing a non–C2-symmetric diamine with a sterically unencumbered salicylaldehyde partner, this approach parts from conventional wisdom in metal-salen catalyst design
and yet the swath of chiral space that results is clearly of value (see
Fig. 9 for a schematic representation of the catalyst discovery and
analysis pathway taken in this study).
From the point of view of chiral ligand development, there are two
principal concepts that emerged from these studies. On the one hand,
the b-D-carbafructopyranosyl-1,2-diamine scaffold is a potentially ‘privileged’ scaffold for the construction of chiral reagents and catalysts
(64), although any such designation certainly must await much more
extensive characterization of this new chiral framework across a
greater breadth of salen-asymmetric and non–salen-asymmetric synthesis space. Thus, to our knowledge, the carbacyclic diamine, when
incorporated into the Co(III)-17c catalyst, displays a chiral bias for the
HKR of 3-phenylpropylene oxide (E = 106 ± 13 at 51% conversion)
comparable to or better than that of the best catalysts reported heretofore, including the best such metal-salen catalyst (E = 96 at 20%
conversion) (110) and the best such evolved enzyme (E =14) (121).
For the HKR of O-phenylglycidol, this metal-salen appears to be
equivalent (E = 95 ± 2 at 51% conversion) to the best known such
catalyst (E = 90 ± 30 at 18 to 54% conversion) (118), and both of these
metal-salens fall just short of the best-evolved enzymes (E = 115; 160)
(107, 119, 120). These experimental observations attest to the potential
of this new chiral scaffold for asymmetric catalysis.
The second interesting conceptual finding here relates to the tunability of these ligands, beyond the stereochemistry, substituent distribution,
and bicyclic nature of the ring system in this non–C2-symmetric chiral1,2-diamine, and beyond its matched or mismatched pairing with
Karukurichi et al. Sci. Adv. 2015;1:e1500066
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Fig. 7. Chin structure versus transition-state model for the HKR of hexene
oxide with catalyst Co(III)-17c. (A) Chin’s Co(III)-salen-aziridine complex (second
aziridine ligand omitted for clarity). (B) TS model for the HKR of hexane oxide with
catalyst Co(III)-17c. Note: The catalyst structure was built from the x-ray
coordinates of the Co(II)-17c structure (Fig. 6C) using the Chin structure as a guide
in Spartan. The preferred substrate enantiomer, (S)-hexene oxide, was docked
(Accelrys) at a Co–O coordination bond length of 1.99 Å, similar to the Co–N
distance in the Chin structure. The O–Co–O–C dihedral angle q in the TS model
is at 24°, within the preferred range described by Jacobsen and co-workers.
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Fig. 8. Streamlined access into the key intermediate toward the b-carbafructopyranosyl-1,2-diamines from D-mannose.

Fig. 9. Overview of the application of mini-ISES to the screening and identification of new chiral scaffolds for asymmetric catalysis. A focused salen
array is screening in parallel by UV/vis spectrophotometry using a micromulticell (20-ml organic layer) so as to bring catalyst loading down to the nanomolar
level. Reporting enzyme output can then be processed to give an in situ readout on sense and magnitude of enantioselectivity. Out of this study, the cobalt17c salen complex emerged as a particularly promising catalyst, indeed the best catalyst reported to date for the HKR of 3-phenyl propylene oxide.
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substituted salicylaldehydes. There is an important additional control
element built into this diamine ligand scaffold, namely, the ability to
modulate ligand shape significantly by introducing or removing an
anomeric effect. Operationally, this amounts to a single heteroatom
change, and to illustrate the underlying principle here, it is probably
of advantage to run the thought experiment in the reverse direction to
the actual experiment here. Thus, crystallographic studies demonstrate
that the carbocyclic diamino-salen, Co(II)-17c, adopts a 5C2 chair-like
structure at its core (Fig. 6C). This confers a shape and overall step
height that is commensurate with a highly enantioselective catalyst,
at least for the HKR chemistry explored here. However, introduction
of the sugar ring oxygen into Co(II)-17c would generate Co(II)-6c in a
5
C2 conformation that suffers from a significant ring dipole-anomeric
C–N dipole reinforcement interaction, that is, an unfavorable anomeric
effect (Fig. 6A). Distortion of the amino sugar core from a 5C2 conformation
to a 3,6B conformation would relieve this dipolar strain, thereby changing the shape of ligand from chair- to boat-like at its core. This, in turn,
fundamentally alters the chiral space that the ligand maps out, and the
step height of the Co-salen complex, ultimately resulting in a changed
chiral bias in the HKR reaction. We believe that this third degree of
modularity of these ligands, grounded in the anomeric effect, adds an
important dimension to their versatility as building blocks for the
construction of salen ligands, as well as other chiral catalyst or reagent
frameworks. In the future, other subtle modifications, such as fluorination, that could have large effects on dipole-dipole interactions (123)
may be strategically employable to modulate such anomeric effect tuning
approaches.
From a much broader catalyst evolution perspective, that substitution of a CH2 for the ring oxygen boosts catalyst selectivity to the same
approximate levels as two different highly evolved (directed evolution)
epoxide hydrolase enzymes (119, 121) attests to the validity of this approach to chiral ligand/catalyst discovery. It is worth noting here that
whereas this type of “isostere” replacement approach is common in
medicinal chemistry, it is much less common in other fields, although
elegant and revealing examples in both chemical biology (for example,
replacement of a native protein b turn with a synthetic prosthetic)
(130, 131) and in asymmetric catalyst design (for example, replacement
of key amide bond with an alkene isostere) (132, 133) have appeared in
recent years. As for the notion that this “tunable” carbafructopyranosyl1,2-diamine–derived ligand scaffold is “privileged,” this will best be
assessed through its further exploration across other metal-salen or
chiral 1,2-diamine–mediated transformations both in these laboratories and beyond.
The ability to miniaturize the ISES method, using an uncomplicated commercially available micromulticell, should make this method
accessible to broader application in chiral catalyst development and
continue to move this methodology further into the nanomolar regime,
in keeping with the trend in catalytic and process chemistry (61). Truly
high-throughput embodiments of mini-ISES will likely require the development of appropriate robotic platforms and automation, for example, building around the proof-of-principle experiments demonstrated
herein with the UV micromulticell. Future studies on the screening side
will be directed at developing related platforms for an even more diverse
array of chemical transformations. For, in the end, as Yoon and Jacobsen
put it, “the identification of new ‘privileged’ ligands and catalysts remains enormously difficult and often requires a degree of serendipity
(64).” It is hoped that the advances in both screening technology and
ligand development described here will facilitate this enterprise.
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MATERIALS AND METHODS
Experimental design
ISES is used here to provide useful estimates of relative reaction rate,
substrate specificity, and % ee of an array of catalyst candidates in parallel. To obtain these data, the assay is performed in a biphasic system.
The upper aqueous enzymatic reporting layer is positioned above the
organic layer, and a UV/vis spectrophotometer is used to monitor the
conversion of NAD to NADH in a semicontinuous fashion across multiple parallel cuvettes or wells, in using the micromulticell. The method
requires that one identify a pair of screening enzymes that display distinct enantioselectivities for the chiral product being generated (1,2propanediol and 1,2-hexanediol here). Toward this end, an array of
KREDs (from Codexis, Sigma, Almac, or expressed in our laboratory)
were screened, and four were selected as appropriate reporting enzymes
for the screen. The enantioselectivity of these enzymes is described below. The miniaturized ISES procedure used for this work is outlined in
detail after the enzyme characterization section. Finally, the secondgeneration synthesis of the carbafructopyranose diamine is reported,
along with procedures to generate our best salen for this HKR and
methods for its crystallization. This section concludes highlighting the
HKR of O-phenylglycidol and 3-phenylpropylene oxide using this catalyst. Further synthetic detail for all compounds can be found in the
Supplementary Materials.
KRED characterization
The enantioselectivity of each reporting enzyme was estimated by comparing the initial velocities of the oxidation for each (R) versus (S) product diols that would be obtained from the HKR of interest across a set of
diol concentrations. Details can be found in the Supplementary Materials.
During earlier HKR-ISES experiments, we estimated the aqueous
layer diol concentration to be in the range of 2.5 to 70 mM under screening conditions. Selectivity parameters appropriate for ISES screening
are chosen on the basis of enantioselectivities observed in this concentration range. For KRED 119, a selectivity factor of 6.5 in favor of the
(R)-1,2-hexanediol was used for ISES determinations. This corresponds
to the selectivity observed in the standard assay cuvette at about 40 mM
diol concentration. KRED 107 proved to be the most difficult reporting
enzyme to parameterize, owing to its very high preference for the (S)antipode of 1,2-hexanediol. In the end, iterative analysis of candidate
fitting factors led us to assign a selectivity factor of 59 for this reporting
enzyme (corresponds approximately to the selectivity of this reporting
enzyme on the lower end of the aforementioned concentration window). Selectivity factors of 8.4 (vS/vR) for TBADH (48) and 6.5 (vS/vR)
for KRED 23 were used for 1,2-propanediol reporting. The complete
set of enantiomeric diol screening data (rate versus concentration) for
each of the selected KRED screening enzymes is provided in the Supplementary Materials.
Procedure of the miniaturized ISES screen
Enzyme standardization.
Stock solutions: The following stock solutions were made for enzyme standardization: 40 mM b-NADP+ (nicotinamide adenine dinucleotide phosphate), 130 mM b-NAD+, TBADH (0.016 mg/ml),
KRED 23 (0.016 mg/ml), KRED 107 (0.002 mg/ml), and KRED 119 (0.002
mg/ml) in 25 mM sodium phosphate buffer (pH 7.0), 2 M (R)-1,2-propanediol in water. Enzyme units were calculated by measuring the rate of
formation of NADPH (reduced form of NADP+) or NADH at 340 nm
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(vide infra). In each case, one SI unit is taken as the amount of enzyme
catalyzing the formation of NADPH (1 mmol/min).
Standardization of TBADH: The assay cuvette contained the following components: 2.2 mM (5 ml of 40 mM stock solution) b-NADP+,
5 ml of TBADH stock solution, 71 ml of 50 mM sodium pyrophosphate
buffer (pH 8.8), and 200 mM (9 ml of 2 M stock) (R)-1,2-propanediol.
The reaction was initiated by the addition of the (R)-1,2-propanediol,
which typically gave a rate of 0.709 abs/min at 25°C at 340-nm wavelength. This was indicative of 0.028 U/ml for the TBADH stock solution for the oxidation of (R)-1,2-propanediol.
Standardization of KRED 23: The assay cuvette contained the following components: 7.2 mM (5 ml of 130 mM stock solution) b-NAD+,
5 ml of KRED 23 stock solution, 71 ml of 50 mM sodium pyrophosphate
buffer (pH 8.8), and 200 mM (9 ml of 2 M stock) (R)-1,2-propanediol.
The reaction was initiated by the addition of the (R)-1,2-propanediol,
which typically gave a rate of 0.540 abs/min at 25°C at 340-nm
wavelength. This is indicative of 0.016 U/ml for the KRED 23 stock solution for the oxidation of (R)-1,2-propanediol.
Standardization of KRED 107: The assay cuvette contained the following components: 2.2 mM (5 ml of 40 mM stock solution) b-NADP+,
5 ml of KRED 107 stock solution, 81 ml of 50 mM sodium pyrophosphate buffer (pH 8.8), and 200 mM (9 ml of 2 M stock) (R)-1,2-hexanediol.
The reaction was initiated by the addition of the (R)-1,2-hexanediol,
which typically gave a rate of 0.124 abs/min at 25°C at 340-nm wavelength. This is indicative of 0.00398 U/ml for the KRED 107 stock solution for the oxidation of (R)-1,2-hexanediol.
Standardization of KRED 119: The assay cuvette contained the following components: 2.2 mM (5 ml of 40 mM stock solution) b-NADP+,
5 ml of KRED 119 stock solution, 81 ml of 50 mM sodium pyrophosphate
buffer (pH 8.8), and 200 mM (9 ml of 2 M stock) (R)-1,2-hexanediol.
The reaction was initiated by the addition of the (R)-1,2-hexanediol,
which typically gave a rate of 0.291 abs/min at 25°C at 340-nm wavelength. This was indicative of 0.00935 U/ml for the KRED 119 stock
solution for the oxidation of (R)-1,2-hexanediol.
Layer composition. Quartz cuvettes with nominal 1-ml volumes
were used in all previous ISES experiments. Here, we describe a general procedure using a 16 multimicrocell array for “cassette” ISES. For
every catalyst, a four-well “cassette screen” was performed over the two
different substrates: propylene oxide and hexene oxide. For propylene
oxide, well A contains TBADH and well B contains KRED 23. For hexene oxide, well C contains KRED 107 and well D contains KRED 119.
The organic layer in wells A and B had the following composition:
10 ml of propylene oxide (8.3 mg, 0.14 mmol), 10 ml of CHCl3, and
0.25 mol % catalyst. The total organic layer volume was maintained
at 20 ml. The organic layer in wells C and D had the following composition: 10 ml of hexene oxide (8.3 mg, 0.08 mmol), 10 ml of CHCl3,
and 0.25 mol % catalyst. The total organic layer volume was maintained at 20 ml. The aqueous layer in well A was 0.1 U of TBADH
[3.6 ml from a stock solution (0.028 U/ml)], 2.2 mM b-NADP+ (5 ml
from a 40 mM stock solution), and 81.4 ml of 50 mM sodium pyrophosphate buffer, pH 8.8. The total volume of the aqueous layer was
maintained at 90 ml. The aqueous layer in well B was 0.1 U of KRED
23 [6.2 ml from a stock solution (0.016 u/ml)], 7.2 mM b-NAD+ (5 ml of
130 mM stock solution), and 78.8 ml of 50 mM sodium pyrophosphate
buffer (pH 8.8). The total volume of the aqueous layer was maintained
at 90 ml. The aqueous layer in well C was 0.0374 U of KRED 107 [9.4 ml
from a stock solution (0.00398 U/ml)], 2.2 mM b-NADP+ (5 ml from a
40 mM stock solution), and 75.6 ml of 50 mM sodium pyrophosphate
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buffer, pH 8.8. The total volume of the aqueous layer was maintained at
90 ml. The aqueous layer in well D was 0.0374 U of KRED 119 [4 ml from
a stock solution (0.00935 U/ml)], 2.2 mM b-NADP+ (5 ml from a 40 mM
stock solution), and 81 ml of 50 mM sodium pyrophosphate buffer, pH
8.8. The total volume of the aqueous layer was maintained at 90 ml.
Step-by-step protocol. It was found to be practical to load the
aqueous layers first. Routinely, 90-ml aqueous layers were loaded into
individuate wells of 16-well quartz micromulticell either with a microsyringe or with a multichannel pipetter. The quartz cell was gently
tapped to keep the layers evenly distributed in the solid quartz apparatus, and then cooled on ice. Then, the organic layers were prepared
by briefly vortexing the catalyst stock in CHCl3 with (±)-propylene
oxide or (±)-hexene oxide in iced microcentrifuge tubes. The
low-volume (20 ml) organic layer was then loaded to each well,
most easily by rapidly syringing below the aqueous layer. For an
example of the primary spectrophotometric data obtained, see
the traces in Fig. 2 of the text (vide supra).
Synthesis of the b-D-carbafructopyranosyl-1,2-diamine
6-(Iodomethyl)-4-methoxy-2,2-dimethyltetrahydro-3aH-[1,3]
dioxolo[4,5-c]pyran-7-ol (21). Methyl-a-D-mannopyranose (9 g,
46.3 mmol) was suspended in 200 ml of toluene at 80°C, and from that
suspension, triphenylphosphine (13.9 g, 53.3 mmol) and imidazole
(10.88 g, 160 mmol) were added, stirring continuously for 10 min at
that temperature. Then, iodine (17.2 g, 66.7 mmol) was added in portions over 0.5 hour. The resulting suspension was vigorously stirred at
80°C for 2 hours, and solution became dark brown. The solution was
cooled, the product was extracted into H2O (3 × 200 ml), and the
aqueous layer was washed with 200 ml of toluene and concentrated
under vacuum. The crude was purified by column chromatography
with pure ethyl acetate (Rf = 0.45 in 50% ethylacetate in acetone), and
pure product (11.3 g, 80%) was obtained as white solid. [a]19D +64.3
(c 1.1, EtOH); 1H NMR (nuclear magnetic resonance) (400 MHz,
D2O) d 3.37 (dd, J = 10.9, 7.1 Hz, 1H), 3.45 (ddd, J = 9.4, 7.1, 2.2 Hz,
1H), 3.57 (app t, J = 9.5, 9.4 Hz, 1H), 3.63 (dd, J = 10.9, 2.2 Hz, 1H),
3.76 (dd, J = 9.5, 3.5 Hz, 1H), 3.93 (dd, J = 3.4, 1.7 Hz, 1H), 4.73 (d, J =
1.4 Hz, 1H); 13C NMR (100 MHz, D2O) d 6.1, 55, 69.8, 70.05, 70.6,
71.5, 101.1; HMRS (FAB) calcd for C7H13IO5Li (M + Li)+ 310.9968,
obsd 310.9961.
6-(Iodomethyl)-4-methoxy-2,2-dimethyltetrahydro-3aH-[1,3]
dioxolo[4,5-c]pyran-7-ol (18). To a solution of 21 (7.5 g, 24.6 mmol,
1 equivalent) in 120 ml of acetone at 0°C was added p-toluenesulfonic
acid (936 mg, 4.92 mmol, 20%), followed by dropwise addition of
dimethoxylpropane (9.1 ml, 73.8 mmol, 3 equivalent) via syringe pump.
The resulting solution was continuously stirred for 3 hours, upon which
time all the starting materials disappeared. The reaction was quenched
by Et3N (1.37 ml, 9.84 mmol, 40%), and organic solvent was evaporated
under reduced pressure. The resulting residues were resuspended in
60 ml of water and extracted with EtOAc (3 × 60 ml). The organic layer
was washed with brine and dried under Na2SO4, filtered and evaporated, and resulted in a pale yellowish liquid as clean product (8.5 g,
95%) without the need for further purification. [a]19D +33.4 (c 1.1, CHCl3);
1
H NMR (400 MHz, CDCl3) d 1.34 (s, 3H), 1.51(s, 3H), 3.30 (dd, J =
10.5, 7.1 Hz, 1H), 3.4d (ddd, J = 9.2, 7.1, 2.4 Hz, 1H), 3.46 (s, 3H), 3.49
(ddd, J = 9.4, 6.9, 3.4 Hz 1H), 3.58(dd, J = 10.6, 2.5 Hz, 1H), 4.10 to
4.12 (m, 2H), 4.91 (s, 1H); 13C NMR (100 MHz, CDCl3) d 6.81, 26.06,
27.97, 55,55, 68.95, 73.06, 75.69, 78.35, 98.33, 109.78; HMRS (FAB)
calcd for C10H18IO5 (M + H)+ 345.0121, obsd 345.0204.
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6-(Iodomethyl)-4,7-dimethoxy-2,2-dimethyltetrahydro-3aH[1,3]dioxolo[4,5-c]pyran (22). To a solution of 18 (160 mg, 0.47 mmol)
in 3 ml of THF at 0°C, imidazole (6.8 mg, 0.1 mmol) and NaH (240 mg,
60% suspension in mineral oil, 6 mmol) were added, followed by the
slow addition of MeI (62 ml, 1 mmol). The resulting solution was continuously stirred at 0°C for 3 hours, upon which time thin-layer chromatography (TLC) showed complete consumption of the starting material.
The reaction is quenched by saturated NH4Cl and extracted with Et2O.
The organic phase was dried, filtered, and evaporated. The crude product
was purified by silica column chromatography to afford 22 as a clear oil
(134 mg, 80%). 1H NMR (400 MHz, CDCl3) d 1.31 (s, 3H), 1.51 (s, 3H),
3.07 (dd, J = 9.6, 6.9 Hz, 1H), 3.27 (dd, J = 10.3, 7.4 Hz, 1H), 3.35
(ddd, J = 9.6, 7.4, 2.2 Hz, 1H), 3.43 (s, 3H), 3.50 (s, 3H), 4.06
(d, J = 5.7 Hz, 1H), 4.14 (app t, 1H); 13C NMR (100 MHz, CDCl3) d
7.15, 26.18, 27.93, 55.91, 59.25, 67.91, 75.76, 78.09, 81.65, 98.21, 109.29; HRMS
ESI calcd for C11H19O5INa (M + Na)+ 381.0175, obsd 381.0164.
(3aR,4S,7S,7aR)-7-Hydroxy-4-methoxy-2,2-dimethyltetrahydrobenzo[d][1,3]dioxol-5(6H)-one (19). Two-step procedure from
18: To 150 mg of 22 (0.42 mmol) in 5 ml of DMF, 0.7 ml DBU
(0.46 mmol) was added at room temperature. The resulting mixture
was stirred at 80°C overnight. The reaction mixture was cooled down,
and 60 ml of EtOAc and 30 ml of saturated NaHCO3 solution were
added. The layers were separated, and the organic layer was washed
with water (3 × 60 ml), and then with brine. The resulting organic
phase was dried with Na2SO4 and evaporated under reduced pressure
to give the product 60% yield: [a]19D +49.1 (c 1.1, CHCl3); 1H NMR
(400 MHz, CDCl3) d 1.33 (s, 3H), 1.48 (s, 3H), 3.46 (d, J = 0.7 Hz,
3H), 3.49 (d, J = 0.7 Hz, 3H), 3.81 (dd, J = 0.8, 4.6 Hz, 1H), 4.16 (ddd,
J = 7.2, 3.8, 0.5 Hz, 1H), 4.26 (dd, J = 7.1, 6.0 Hz, 1H), 4.43 (d, J = 0.8 Hz,
1H), 4.64 (d, J = 0.8 Hz, 1H), 4.86 (s, 1H); 13C NMR (100 MHz, CDCl3)
d 24.74, 26.89, 56.25, 57.91, 74.58, 75.86, 77.97, 93.22, 100.23, 109.80,
151.94; HMRS (FAB) calcd for C11H18O5Li (M + Li)+ 237.031, obsd
237.1316. For the one-pot process: 1.3 g of 18 (3.78 mmol) was dissolved in 40 ml of DMF, cooled to 0°C, and 0.47 ml MeI (7.56 mmol)
was added, followed by 51 mg of imidazole (0.76 mmol, 20%) and 272 mg
of NaH (11.3 mmol, washed with hexane to remove mineral oil). The
reaction mixture was continuously stirred at 0°C for 3 hours, and TLC
shows all SM converted to alkene product and iodide intermediate. The
reaction mixture was continuously stirred at room temperature overnight.
TLC showed a single spot as the eliminated product. Workup: The
reaction mixture was added 60 ml of EtOAc and 30 ml of saturated
NaHCO3 solution. The layers were separated, and the organic layer was
washed with water (3 × 60 ml), and then with brine. The resulting
organic phase was dried with Na2SO4 and evaporated under reduced
pressure to give 19 as a colorless oil (0.85 g, 98%).
(3aR,4S,7S,7aR)-7-Hydroxy-4-methoxy-2,2-dimethyltetrahydrobenzo[d][1,3]dioxol-5(6H)-one (20). 19 (5.21 g, 22.6 mmol) was
dissolved in 120 ml of solvent containing 2:2:1 volume ratio of acetone,
dioxane, and H2O. The solution was cooled to 0°C, and Pd(OAc)2
(10 mol %) was added in portions. The reaction mixture was kept at
0°C for 12 hours, and the TLC showed complete consumption of the
starting material. The reaction mixture was diluted with saturated
NaCl and extracted with EtOAc (3 × 60 ml). The resulting organic
phase was dried with Na2SO4, filtered, and evaporated under reduced
pressure. The residue was purified by column chromatography (Rf = 0.25
at 50% EA in hexanes), and 4.15 g of product was obtained (85% total
yield, which contains about 8% of the 5-epimer). For the major epimer:
[a]19D −32.9 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) d 1.30 (s, 3H),
Karukurichi et al. Sci. Adv. 2015;1:e1500066

10 July 2015

1.41 (s, 3H), 2.42 (dd, J = 18.3, 6.2 Hz, 1H), 2.75 (dd, J = 18.3, 5.0 Hz,
1H), 3.45 (s, 3H), 3.56 to 3.63 (m, 1H), 3.70 (d, J = 5.2 Hz, 1H), 4.27
(app t, J = 6.9, 5.4 Hz, 1H), 4.39 (dd, J = 7.0, 5.3 Hz, 1H), 5.51 to
5.55 (m, 2H); 13C NMR (100 MHz, CDCl3) d 24.26, 26.73, 41.86,
59.00, 67.50, 76.71, 77.04, 83.89, 109.77, 204.70; HRMS FAB calcd
for C10H17O5 (M + H)+ 217.1076, obsd 217.1073.
(3aR,4S,7aR)-4-Methoxy-2,2-dimethyl-3a,4-dihydrobenzo[d]
[1,3]dioxol-5(7aH)-one (23). To a solution of 20 (692 mg, 3.2 mmol)
in 10 ml of CH2Cl2 at 0°C, diisopropyethyl amine (1.11 ml, 6.4 mmol)
and 1 crystal of DMAP were added. Then, MsCl (371 ml, 4.8 mmol) was
added dropwise, and the resulting solution was stirred at room temperature until SM disappeared. The reaction was quenched by the addition
of saturated NH4Cl and extracted with CH2Cl2; column chromatography purification afforded 23 as a clear oil (480 mg, 76% yield). [a]
19
1
D −84.4 (c 0.65, CHCl3); H NMR (400 MHz, CDCl3) d 1.35 (d, J =
4.26 Hz, 3H), 1.40 (d, J = 4.38 Hz, 3H), 3.45 (d, J = 4.5 Hz, 3H), 3.82
(app t, J = 4.4, 5.2 Hz, 1H), 4.47 (m, 1H), 4.73 (m, 1H), 5.99 (dd, J =
10.25, 4.53 Hz, 1H), 6.64 to 6.69 (m, 1H); 13C NMR (100 MHz,
CDCl3) d 26.29, 27.82, 59.17, 71.12, 76.68, 81.07, 110.96, 128.08,
143.32, 194.96; HRMS FAB calcd for C 10 H 14 LiO 4 (M + Li) +
205.1052, obsd 205.1046.
(3aR,4S,7aR)-4-Methoxy-2,2-dimethyltetrahydrobenzo[d][1,3]
dioxol-5(6H)-one (12). To a solution of 23 (200 mg, 1.0 mmol) in
EtOAc (10 ml) was added 20% Pd(OH)2/C (20 wt%, 40 mg). The resulting mixture was hydrogenated at 20 psi for 1 hour, and the catalyst
was then filtered off a pad of Celite and washed with EtOAc. The filtrate was evaporated to give the ketone 12 as a colorless oil (202 mg,
100% yield). [a]19D −69.6 (c 1.1, CHCl3); 1H NMR (400 MHz, CDCl3)
d 1.33 (s, 3H), 1.43 (s, 3H), 2.09 to 2.14 (m, 1H), 2.21 to 2.30 (m, 2H),
2.46 to 2.55 (m, 1H), 3.41(s, 3H), 4.31 (dd, J = 6.8, 4.6 Hz, 1H), 4.41 to
4.48 (m, 1H); 13C NMR (100 MHz, CDCl3) d 23,70, 24.38, 26.72,
32.68, 58.80, 72.29, 78.05, 84.23, 109.22, 207.53; HRMS (CI) calcd
for C11H19O3 (M + H)+ 199.1334, obsd 199.1338.
(3aR,4R,7aR)-4-Methoxy-2,2-dimethyl-5-methylenehexahydrobenzo[d][1,3]dioxole (13). To a stirred ice-cold solution of Ph3PCH3Br
(1.32 g, 2.14 mmol, 1.5 equivalent), 1.3 M BuLi in hexanes (1.5 ml,
2.0 mmol, 1.4 equivalent) was slowly added. The resulting yellow solution was stirred for 10 min at 0°C, and the ethereal solution of the
ketone (288 mg, 1.44 mmol, 1 equivalent) was added slowly. Immediate
precipitation appeared, and the resulting suspension was stirred overnight and quenched with 1 M NaOH. The product was extracted with
ether, washed with brine, and dried over Na2SO4. Removal of solvent
under reduced pressure provided the crude product. The product was
purified by column chromatography on silica gel to yield the terminal
olefin 9 (228 mg, 80%) as a clear liquid. [a]19D −96.2 (c 1.0, CHCl3);
1
H NMR (400 MHz, CDCl3) d 1.26 (d, J = 2.5 Hz, 3H), 1.41 (d, J = 2.6 Hz,
3H), 1.77 to 1.81 (m, 1H), 1.86 to 1.92 (m, 1H), 2.11 to 2.14 (m, 1H), 2.20
to 2.27 (m, 1H), 3.30 (d, J = 2.8 Hz, 3H), 3.61 (dt, J = 3.8, 1.1 Hz, 1H),
3.93 to 3.97 (m, 1H), 4.23 to 4.26 (m, 1H), 4.92 (d J = 1.08 Hz, 3H); 13C
NMR (100 MHz, CDCl3) d 25,32, 25.78, 26.15, 27.49, 57.25, 73.48, 79.43,
83.23, 108.18, 111.20, 142.53; HRMS (CI) calcd for C11H19O3 (M + H)+
199.1334, obsd 199.1338.
(3aR,4R,5S,7aR)-5-Azido-5-(azidomethyl)-4-methoxy-2,2dimethylhexahydro-benzo[d][1,3]dioxole (b-diazide) (15). A dry
flask was charged with NaN3 (442 mg, 6.8 mmol, 5 equivalent), Mn
(OAc)3-2H2O (1.1 g, 4.1 mmol, 3 equivalent), and CH3CN (7 ml) and
nitrogen gas were bubbled through the mixture. Then, the reaction
mixture was cooled down to −20°C, and 13 (270 mg, 1.36 mmol,
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1 equivalent) was added to it dropwise. The reaction was initiated by the
slow addition of TFA (0.21 ml). The reaction mixture was slowly
warmed up to room temperature. After 3 hours, aqueous NaHSO3 solution was added, and the reaction mixture was extracted with CH2Cl2.
The organic layer was washed with satd Na2CO3 and dried. Column
chromatography (10% Et2O in hexanes) gave two fractions with very
close Rf values, with 80% yield. Fraction 1 yielded b-diazide 15 as a
clear oil (84 mg, 22%); [a]19D −84.2 (c 1.05, CHCl3); 1H NMR (400 MHz,
CDCl3) d 1.32 (s, 3H), 1.48 (s, 3H), 1.59 (m, 1H), 1.71 (dt, J = 14, 5.5 Hz,
1H), 1.92 (m, 2H), 3.22 (d, J = 7.3 Hz, 1H), 3.53(s, 3H), 3.55 (d, J =
12.1 Hz, 1H), 3.62 (d, J = 12.1 Hz, 1H), 4.13 (dd, J = 7.2, 5.4 Hz 1H),
4.25 (m, 1H); 13C NMR (100 MHz, CDCl3) d 21.8, 26.2, 26.3, 28.4,
55.3, 60.2, 65.8, 73.9, 79.7, 82.5, 108.5; HRMS (FAB) calcd for
C13H19N6O3 (M + H)+ 283.1519, obsd 283.1530. Fraction 2 yielded
the a-diazide 14 as a clear oil (221 mg, 58%); [a]19D −110.3 (c 1.0,
CHCl3); 1H NMR (400 MHz, CDCl3) d 1.31 (s, 3H), 1.49 (s, 3H), 1.64
(m, 2H), 1.83 (m, 1H), 2.03 (m, 1H), 3.18 (d, J = 13.4 Hz, 1H), 3.35
(d, J = 7.1 Hz, 1H), 3.55 (s, 3H), 3.68 (d, J = 13.4 Hz, 1H), 3.90 (app t,
J = 6.8 Hz, 1H), 4.21 (m, 1H); 13C NMR (100 MHz, CDCl3) d 22.6,
25.4, 26.1, 28.2, 51.2, 60.4, 66.2, 73.3, 79.2, 85.2, 108.8; HRMS (FAB)
calcd for C11H18N6O3Li (M + Li)+ 289.1600, obsd 289.1596.
(3aR,4R,5S,7aR)-5-(Aminomethyl)-4-methoxy-2,2-dimethylhexahydrobenzo-[d][1,3]dioxol-5-amine (b-diamine) (17). b-Diazide
15 (321 mg, 1.14 mmol) was dissolved in EtOH (10 ml), and 32 mg
of 10% Pd/C was added. The resulting suspension was hydrogenated at
52 psi for 12 hours, resulting total reduction to give b-diamine 17 (262 mg,
100%). [a]19D −61.5 (c 0.76, CHCl3); 1H NMR (400 MHz, CDCl3) d
1.30 (br s, 4H), 1.33 (s, 3H), 1.5 (s, 3H), 1.54 (dt, J = 13.5, 4.6 Hz, 2H),
1.87 (br d, J = 13.2 Hz, 1H), 2.04 (tt, J = 13.3, 4.7 Hz, 1H), 2.6 (d, J =
12.7 Hz, 1H), 2.63 (d, J = 12.7 Hz, 1H), 3.08 (d, J = 7.2 Hz, 1H), 3.51
(s, 3H), 4.16 (app t, J = 6.8 Hz, 1H), 4.26 (m, 1H); 13C NMR (100 MHz,
CDCl3) d 21.9, 26.4, 27.7, 28.4, 51.7, 56.0, 60.0, 74.4, 80.2, 84.1, 107.7;
HRMS (FAB) calcd for C13H23N2O3 (M + H)+ 231.1709, obsd 231.1700.
a-Diamine (16). a-Diazide 14 (168 mg, 0.6 mmol) was dissolved
in EtOH (5 ml), and 20 mg of 10% Pd/C was added. The resulting suspension was hydrogenated at 52 psi for 12 hours, resulting total reduction to give a-diamine 16 (135 mg, 100%). [a]19D −54.7 (c 0.35, CHCl3);
1
H NMR (400 MHz, CDCl3) d 1.30 (br s, 3 H), 1.37 to 1.47 (m, 4 H),
1.48 (s, 3 H), 1.54 (dt, J = 13.6, 4 Hz, 1 H), 1.60 to 1.70 (m, 1 H), 1.92
(qt, J = 4, 15.6 Hz, 1 H), 2.42 (d, J = 13.2 Hz, 1 H), 2.67 (d, J = 13.2 Hz,
1 H), 3.14 (d, J = 7.2 Hz, 1 H), 3.51 (s, 3 H), 3.96 (dd, J = 5.6, 7.6 Hz,
1 H), 4.20 to 4.24 (m, 1 H); HRMS (ESI) calcd for C13H23N2O3 (M + H)+
231.1709, obsd 231.1706.
General procedure for the synthesis and crystallization of
the Co(II)-salen complexes
Co(II)-17c used as an example: To an oven-dried round bottom flask,
diamine 17 (65 mg, 0.28 mmol, 1 equivalent), 3,5-diiodosalicylaldehyde
(190 mg, 0.51 mmol, 1.8 equivalent), and freshly distilled ethanol (3 ml)
were added. The reaction mixture was heated at 50°C overnight. TLC
indicated completion of the reaction. The reaction was concentrated in
vacuo. The residue was purified by silica gel column chromatography
(eluting with EtOAc/hexanes: 0 to 30%) to afford salen 17c as a yellow
solid (211 mg, 88%). [a]19D −138.4 (c 1.0, CHCl3); 1H NMR (400 MHz,
CD3Cl3) d 1.33 (s, 3H), 1.53 (s, 3H), 1.86 to 1.88 (m, 1H), 1.95 to 1.97
(m, 2H), 2.06 to 2.08 (m, 1H), 3.41 (d, J = 7.7 Hz, 3H), 3.59 (s, 3H), 3.98
(d, J = 12.5 Hz, 1H), 3.83 (d, J = 12.5 Hz, 1H), 4.8 (dd, J = 7.5, 5.4 Hz,
1H), 4.28 (br s, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.51 (d, J = 1.9 Hz, 1H),
Karukurichi et al. Sci. Adv. 2015;1:e1500066

10 July 2015

8.04 (d, J = 1.9 Hz, 1H), 8.05 (d, J = 1.9 Hz, 1H), 8.12 (s, 1H), 8.37 (d, J =
1.73 Hz, 1H), 14.05 (s, 1H), 14.83 (s, 1H); 13C NMR (100 MHz, CD3Cl3)
d 21.8, 26.3, 27.4, 28.4, 60.8, 63.9, 65.3, 73.7, 78.6, 79.3, 79.7, 83.9, 87.3, 88.9,
108.4, 119.4, 119.6, 139.9, 140.6, 149.0, 149.2, 160.3, 162.3, 163.8, 165.4;
HMRS (FAB) calcd for C25H27N2O5I4 (M + H)+ 942.8021, obsd 942.8115.
The ligand 17c (116 mg, 0.14 mmol, 1 equivalent) was dissolved in
1 ml CH2Cl2, and a methanolic (1 ml) solution of cobalt (II) acetate
tetrahydrate (34 mg, 0.14 mmol, 1 equivalent) was added via cannula
under Ar. The Co(II)-17c complex precipitated out after stirring for 30
min. After filtration, the solid was dried under vacuum to afford 17c
(102 mg, 68%) as a red solid.
A 1-dram vial was taken, and the inner walls were scratched with a
glass pipette to get a visibly rough surface. This vial was charged with
15 mg of the Co(II)-17c complex, and about 1 ml of CHCl3 was
added to it. The contents were gently warmed in a ~ 60°C water bath
to fully dissolve the solid. Methanol was slowly added at room temperature until the solution turned turbid. The mixture was heated again, and
the solution became clear. The vial was capped and cooled down slowly.
After 2 days, red crystals were harvested and sent for diffraction.
General procedure for HKR reactions using the
Co(III)-17c catalyst
The Co(II)-17c complex was taken up in CH2Cl2 (2 ml) and stirred
with 3,5-dinitrobenzoic acid (1 equivalent) in open air. The oxidation
could be followed by TLC {formation of a greenish-brown spot of lower
Rf [Co-(III) complex] from the visibly red, higher Rf spot characteristic
of the Co(II)-17c salen}. When TLC indicated the completion of the
reaction, the solvent was evaporated, and the Co(III)-17c-3,5-DNB
complex was further dried in vacuo. The Co(III)-17c catalyst was used
directly for HKR experiments, under ISES (biphasic) conditions or
under typical neat or one-phase flask conditions.
Two different general procedures were adapted on the basis of the
ease of handling of the epoxides (see the Supplementary Materials for
a complete set of examples and characterization data). Representative
examples are provided herewith.
Procedure A: 3-Phenoxy-1,2-epoxypropane
(O-phenylglycidol)—HKR
Catalyst Co(III)-17c-3,5-DNB (5 mg, 0.005 mmol, 0.5 mol % loading)
was mixed with 3-phenoxy-1,2-epoxypropane (150 mg, 1 mmol) and
300 ml of CH2Cl2. The mixture was cooled to 0°C, and the reaction
was initiated by adding 9 ml (0.5 equivalent) of water, and stirring was
continued for 20 hours at room temperature. After the reaction, silica
gel column chromatography provided the unreacted 3-phenoxy-1,2epoxypropane (71 mg, 47%, eluting with 50% ether/pentane) and 3phenoxy-1,2-propanediol (O-phenylglycidol; 77 mg, 46%, further eluting
with 10% methanol/ether).
3-Phenoxy-1,2-epoxypropane. 1H NMR (400 MHz, CDCl3) d 2.73
to 2.79 (m, 1H), 2.89 to 2.91 (t, J = 4.8 Hz, 1H), 3.33 to 3.37 (m, 1H),
3.94 to 4.04 (m, 1H), 4.19 to 4.25 (m, 1H), 6.88 to 7.00 (m, 3H), 7.23
to 7.33 (m, 2H); [a]19D obsd +22.3 (for 96% ee of S), [a]19D +23.0,
calcd (c = 1.4, CHCl3). The enantiomers of this epoxide were resolved
via HPLC (Chiralcel OD column). For the epoxide (hexanes/i-PrOH
87:13, flow rate 1 ml/min), minor isomer, tR = 8.2 min (R) and major
isomer, tR = 12.4 min (S).
3-Phenoxy-1,2-propanediol. 1H NMR (400 MHz, CDCl3) d 2.54
(br s, 1H), 3.03 (br s, 1H), 3.71 to 3.84 (m, 2H), 4.01 to 4.11 (m, 3H),
6.88 to 6.98 (m, 3H), 7.23 to 7.30 (m, 2H); [a]19D obsd −9.1 (for 92% ee
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of R), [a]19D −9.9, calcd (c = 1.4, CHCl3), [lit.(110) [a] 23D −10.0 (c = 1.9,
EtOH)]. The enantiomers of the diol were also resolved using a Chiralcel
OD column. For the diol (hexanes/i-PrOH 90:10, flow rate 1 ml/min),
major isomer, tR = 15.6 min (R) and minor isomer, tR = 33.7 min (S).
Procedure B: 1,2-Epoxy-3-phenylpropane—HKR
Starting from epoxy-3-phenylpropane (315 mg, 2.3 mmol), treatment
with catalyst Co(III)-17c-3,5-DNB (24.8 mg, 0.023 mmol, 1 mol %)
and 22 ml (0.5 equivalent) of water at 0°C over 12 hours resulted in
51% conversion as judged by 1H NMR (small aliquot). The crude reaction
mixture was then added to a freshly prepared solution of sodium phenylselenide, leading to direct epoxide ring opening with phenyl selenide
anion. After workup and SiO2 column chromatography, both the
seleno-alcohol (329 mg, 48%, 0→50% ether in pentane) and 3-phenyl1,2-propanediol (175 mg, 49%, 50→0% ether in EtOAc) were obtained.
1-(Phenylseleno)-3-phenyl-2-propanol. 1H NMR (400 MHz,
CDCl3) d 2.36 (d, J = 3.6 Hz, 1H), 2.86 to 2.88 (m, 2H), 2.91 to 2.96
(m, 1H), 3.10 to 3.14 (m, 1H), 3.92 to 3.96 (m, 1H), 7.17 to 7.30 (m, 8H),
7.47 to 7.50 (m, 2H); [a]19obsd −31.7 (for 97% ee of R), [a]19D −32.4,
calcd (c = 1.0, CHCl3). The seleno-alcohol was further derivatized using
a classical Mosher ester procedure. The enantiomeric excess of the epoxide was subsequently estimated from integration of the methoxy
groups on the two diastereomers (see the Supplementary Materials for detailed derivatization conditions and 1H NMR of the two Mosher esters);
major isomer, d = 3.47 ppm (R) and minor isomer d = 3.36 ppm (S).
3-Phenylpropane-1,2-diol. 1H NMR (400 MHz, CDCl3) d 2.68
to 2.78 (m, 2H), 3.44 to 3.48 (m, 2H), 3.63 (d, J = 10.8 Hz, 2H), 3.89
(d, J = 5.6 Hz, 1H), 7.18 to 7.31 (m, 5H); [a]19obsd −21.5 (for 92% ee
of S), [a]19D −23.3, calcd (c = 1.0, CHCl3), [lit.(134) [a]D −18.6 (c =
1.3, CHCl3) for (S)-diol, lit.(135) [a]20D +20.4, (c = 1.0, CHCl3) for
(R)-diol, lit.(136) [a]20D +15.0, (c = 1.0, CHCl3) for (R)-diol, lit. (137)
[a]D −29.0, (c = 1.2, EtOH) for (S)-diol]. The enantiopurity of the
1,2-diol was established by chiral HPLC (Chiralcel OD; hexane/
i-PrOH 92:8, flow rate: 1 ml/min), minor isomer, tR = 12.1 min (R)
and major isomer, tR = 13.2 min (S).

SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/1/6/e1500066/DC1
Complete description of ISES reporting enzymes; synthetic procedures and full spectral
characterization for synthetic intermediates, chiral HPLC traces used to determine
enantiopurity of all HKR products, step height analysis from the Co-salen x-ray crystal
structures (93 pages).
Fig. S1. Enantioselectivity of the new KRED-119 reporting enzyme.
Fig. S2. Enantioselectivity of the new KRED-107 reporting enzyme.
Fig. S3. Enantioselectivity of the new KRED-23 reporting enzyme.
Fig. S4. Geometric parameters used to estimate step height for the carbafructopyranose-based
Co-salen complexes.
Fig. S5. Step heights from x-ray crystal structures of the carbafructopyranose-based Co-salen
complexes.
Table S1. HRMS characterization of Co(III)-salen catalysts.
Table S2. HKR under standard “round bottom flask conditions” with Co(III)-salen-3,5-DNB complexes.
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